Hepatocyte

LifeNet Health to highlight emerging life sciences research platforms at 2019 BIO International Convention

Retrieved on: 
Monday, June 3, 2019
Branches of biology, Air Methods, Translational research, Hepatocyte, Biology, Health

PHILADELPHIA, June 3, 2019 /PRNewswire/ --LifeNet Health (Booth #3649) will feature its portfolio of premium research solutions, including high-quality human primary hepatocytes and islets, at the BIO International Convention June 3-6 in Philadelphia.

Key Points: 
  • PHILADELPHIA, June 3, 2019 /PRNewswire/ --LifeNet Health (Booth #3649) will feature its portfolio of premium research solutions, including high-quality human primary hepatocytes and islets, at the BIO International Convention June 3-6 in Philadelphia.
  • "Exceptional medical challenges demand exceptional solutions," said Rony Thomas, LifeNet Health President and CEO.
  • With our growing islet program as well, LifeNet Health has become researchers' first choice for premium primary cells and tissues to support discoveries."
  • This portfolio of research solutions stands apart in the life sciences industry and provides vital resources for translational research.

Scientists Bioengineer Human Liver Disease in the Lab to Find New Treatments

Retrieved on: 
Thursday, May 30, 2019
Branches of biology, Biology, Stem cells, Cell biology, Organoid, Tissue engineering, Liver, Hepatocyte, Histology

CINCINNATI, May 30, 2019 /PRNewswire/ -- Scientists successfully bioengineered human liver organoids that faithfully mimic key features of fatal liver disease in the laboratory.

Key Points: 
  • CINCINNATI, May 30, 2019 /PRNewswire/ -- Scientists successfully bioengineered human liver organoids that faithfully mimic key features of fatal liver disease in the laboratory.
  • "We developed a reproducible method to bioengineer complex, multicellular human liver organoids using pluripotent stem cells derived from healthy human donors and those with liver disease," he said.
  • "These organoids generate different types of liver cells like hepatocytes, stellate and Kupffer-like cells, and they accurately recreate in the lab inflammation, fibrosis and other features of liver disease.''
  • The organoids were able to recreate liver disease in the lab in a step-by-step, successive manner similar to Wolman disease in children.

INDIGO Biosciences Announces Release of Gene Expression Kit Utilizing upcyte® Hepatocytes

Retrieved on: 
Tuesday, December 11, 2018
Biology, Hepatocyte, Assay, Nature

STATE COLLEGE, Pa., Dec. 11, 2018 /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte hepatocytes to their portfolio.

Key Points: 
  • STATE COLLEGE, Pa., Dec. 11, 2018 /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte hepatocytes to their portfolio.
  • INDIGO's assay kit utilizes optimized upcyte hepatocytes, which are human donor-derived hepatocytes established by upcyte technologies GmbH.
  • The upcyte hepatocytes combine the characteristics and advantages of primary hepatocytes with the added practical advantage of having access to the same donor cells for use in iterative, large-scale testing over extended periods.
  • "The addition of the assay kit for the Expression Profiling of Clinically Relevant CYPs Utilizing upcyte Hepatocytes to our portfolio represents a significant expansion in drug discovery capabilities.

Prometic Presents New Data on NASH Drug Candidate PBI-4547

Retrieved on: 
Friday, June 22, 2018
Hepatitis, Anatomy, Medicine, Steatohepatitis, Biology, GPR84, Liver disease, Hepatocyte, Liver, Non-alcoholic fatty liver disease

"NASH", or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes.

Key Points: 
  • "NASH", or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes.
  • PBI-4547 is an orally active drug candidate and analogue to PBI-4050.
  • Prometic uncovered a novel antifibrotic pathway involving these receptors, showing that GPR40 is protective and GPR84 is deleterious in fibrotic diseases.
  • Prometic ( www.prometic.com ) is a biopharmaceutical corporation with two drug discovery platforms focusing on unmet medical needs.